Plasmin generation by equimolar concentrations of tissue plasminogen activator (t-PA), pro-urokinase (pro-UK), and urokinase (UK), and a twofold higher concentration of a plasmin-resistant mutant rpro-UK (Ala-158-pro-UK) was measured on a microtiter plate reader. The promoting effects on this reaction of equimolar concentrations of fibrinogen, soluble fibrin (Desafib), CNBr fragment FCB-2 (an analogue of fragment D), or purified fragment E-2 were compared. Plasmin generation by t-PA was moderately promoted by fibrinogen, substantially promoted by Desafib and FCB-2, but not at all promoted by fragment E-2. By contrast, plasmin generation by pro-UK or by Ala-158-pro-UK was not promoted either by fibrinogen, Desafib, or FCB-2, but was significantly promoted by fragment E-2. Plasmin generation by UK was not significantly promoted by any of the fibrin(ogen) preparations. Treatment of fragment E-2 by carboxypeptidase-B (CPB), eliminated its promotion of pro-UK and Ala-158-pro-UK-induced plasmin generation. Pretreatment of FCB-2 with plasmin slightly potentiated its promotion of t-PA activity. This effect of plasmin pretreatment of FCB-2 was reversed by CPB treatment. Plasmin pretreatment of FCB-2 did not induce any promotion of activity in pro-UK or Ala-158-pro-UK.
Introduction
In previous studies ofclot lysis in a plasma milieu, it was shown that tissue plasminogen activator (t-PA)' and pro-urokinase 1. Abbreviations used in this paper: CPB, carboxypeptidase-B; pNA, p-nitro analine; pro-UK, pro-urokinase; t-PA, tissue plasminogen activator.
(pro-UK) had certain complementary properties at fibrin-specific doses. Clot lysis by t-PA was more linear and relatively unaffected by plasmin pretreatment of the clot. By contrast, clot lysis by pro-UK was preceded by a lag phase which was strongly attenuated by plasmin-pretreatment of fibrin. This effect of plasmin could be reversed by subsequent treatment of the clot with carboxypeptidase-B (1). These findings appeared to suggest that t-PA and pro-UK activated different plasminogen substrates in the fibrin clot. It was proposed that t-PA predominantly activated plasminogen bound to intact fibrin, as previously suggested by Verheijen et al. (2) , whereas pro-UK activated plasminogen bound to COOH-terminal lysines, either on the E-domain or on the a-chain of partially degraded fibrin.
The present study was undertaken to critically examine this hypothesis in a purified system by comparing the promoting effects of fibrinogen, CNBr fragment FCB-2 (an analogue of fragment D), and purified fragment E-2 on plasminogen activation by t-PA, pro-UK, a plasmin-resistant mutant rpro-UK (Ala-158-pro-UK), and urokinase (UK).
Methods
Materials. Pro-UK, purified from a transformed human kidney cell line, was obtained from Collaborative Research Inc. (Lexington, MA). It contained < 1% two-chain UK and was further purified by treatment with DFP as previously described (3) . A plasmin-resistant mutant form of r-pro-UK was constructed by site-directed mutagenesis of Lys-158 --Ala-158 (Ala-158-pro-UK) and was obtained from the same source. Two-chain, 55 kD UK was obtained from Green Cross (Osaka, Japan). Single chain t-PA was obtained from Boehringer Mannheim GmbH (Mannheim, Germany). The concentration ofthe plasminogen activators was standardized with the t-PA and UK International Reference Preparations (National Institute for Biological Standards and Controls, London, UK). For this purpose the pro-UK was first converted to UK by incubation with plasmin as previously described (4) .
The concentration of the Ala-l 58-pro-UK was determined from the absorbance using the extinction coefficient of pro-UK (Elso. = 13.6).
The Ala-158-pro-UK had an activity against synthetic substrate or against plasminogen that was 0.5% that of UK, which is similar to the 0.4% reported by Pannell et al. (3) (Greenwich, CT).
Preparation of fragment E-2. Fragment E-2 was selected from among the fragments E characterized by Olexa et al. (7) because it can be purified most readily and because it is relatively stable. NaCl-0.0I M CaC12, pH 7.4, at a final concentration of 10 mg/ml. The solution was equilibrated to 370C and Glu-plasminogen (0.025 mg/ml) and streptokinase (Hoechst Pharmaceuticals, Somerville, NJ) (7.5 IU/ ml) were added immediately before the addition of highly purified thrombin (8 NIH U/ml). The reaction mixture was incubated (370C) for 3 h. Digestion was arrested by the addition of aprotinin (Trasylol, 100 KIU/ml; Miles Inc., West Haven, CT), epsilonaminocaproic acid (0.02 M), and EDTA (0.02 M).
The digest was then applied onto a Sephacryl S-200 (Pharmacia Fine Chemicals, Piscataway, NJ) column (2.5 X 160 cm) equilibrated with 0.3 M NH4HCO3 and eluted with the same buffer. Fragments E were obtained from pool B, whereas pool A contained DD-E. The latter pool was lyophilized and dissolved in 0.05 M sodium citrate, 3 M urea, pH 5.5, and incubated (370C) for 3 h as described by Varadi and Patthy (9) . Fragment E-2 was separated from DD-E by gel filtration on a Sephacryl S-300 column (2.5 X 160 cm) equilibrated with 0.05 M sodium citrate, 3 M urea. The purified E-2 preparation was desalted and lyophilized.
The preparation was tested for plasmin activity with S2251 and trace activity was found. To remove this, the preparation was treated with EACA (0.5 M) and diisopropylflurophosphate (5 mM) for 1 h (370C), and then dialyzed exhaustively against buffer (0.05 M sodium phosphate, 0.15 M NaCl, pH 7.8).
The concentration offragment E-2 was determined from the absorbance (280 nm) divided by the molecular extinction coefficient offragment E-2 (E" = 10.0). It was additionally measured using a protein assay kit (Bio-Rad Laboratories, Inc., Richmond, CA). The final preparation was examined by gradient (5-15%) SDS-PAGE.
Plasmin Effects offibrin(ogen) or its derivatives on plasmin generation by plasminogen activators. The time-absorbance curves ofthe stimulation by fibrinogen, FCB-2, Desafib and fragment E-2 on plasminogen activation by t-PA, pro-urokinase, Ala-I 58-pro-UK, and UK were determined by measuring the OD increase in the reaction mixture with time at 410 nm against a reference wavelength of 490 nm (410/490 nm) on the microtiter plate reader. The reaction mixture contained 1.5 mM S2251, 0.24 MM Glu-plasminogen, I MM of the stimulator and 0.5 nM of the plasminogen activator (except for Ala-158-pro-UK which was 1.0 nM) in 0.05 M sodium phosphate, 0.15 M NaCl, 0.2% BSA, 0.01% Tween 80, pH 7.8 at room temperature. The effect ofplasmin and CPB treatment of the stimulators was also evaluated. Each experiment was done in quadruplicate and all comparisons were made only of data from the same experiment. At the concentrations used, neither UK nor t-PA had any effect on S225 1. Methodology for determining the reaction rates of the activators.
The rate of each of the reactions was determined from the absorbance as a function of time, expressed as follows:
where Vi is the reaction rate and B the background (toabsorbance). This equation is based on the following analysis:
Plasminogen activation by t-PA, UK, or Ala-I 58-pro-UK, coupled with measuring plasmin generation with S225 1, can be described by the following two reactions:
o Peptide + pNA (AA410l490,m).
The time-absorbance curves of these reactions can be plotted from the assays. The value for the reaction rate can then be determined directly by curve fitting using the integrated rate equation adapted from Chibber et al. (10) .
where e is the molar extinction coefficient for p-nitro analine (pNA) in a I00-Ml well, A is absorbance and subscript i represents the concentration used, B is the value for the background (B = AO), and
Curve fitting was performed on early time points, before depletion of substrates became significant, using the Enzfitter program (ElsevierBiosoft, Cambridge, UK). The Vi was directly obtained by nonlinear regression analysis.
Although pro-UK is problematic in that it is converted to UK during the course ofthe assay, for the purpose ofthe comparison, the same analytic procedure was used. However, to minimize the effect of UK generation, analysis was restricted to earlier time points (< 120 min).
Effect offragment E-2 on plasmin generation by Ala-158-pro-UK. Time absorbance curves of plasminogen activation by Ala-158-pro-UK were obtained in the presence of a range of concentrations (0-20 MM) of fragment E-2 using the method described above. The concentration of the other reactants was not changed from that used in the other experiments. The reaction mixture contained S-2251 (1.5 mM), Glu-plasminogen (0.24 MM), and Ala-158-pro-UK (1.0 nM) and was incubated for 60 min. The promotion of the rate ofplasmin generation by fragment E-2 (2.5, 5, 10, 20 AM) was determined. The results were expressed as a ratio of the reaction rate in the presence versus the absence of the ligand.
In a control experiment, FCB-2 (20 MM) was substituted for fragment E-2.
Results
Characterization of the fragment E-2 preparation by SDS-PAGE (Fig. 1) . The fragment E was purified from the DD-E complex and therefore corresponded to either fragment E-1 or E-2, because fragment E-3 does not bond to DD (7) . The preparation was homogenous and fragment E-1 and E-2 were resolved by SDS-PAGE. Moreover, the final preparation was shown to comigrate with a commercial preparation of fragment E-2 (American Bioproducts, Parsippany, NJ) (data not shown). A trace plasmin contaminant in the preparation was removed as described above. Fig. 1 shows the fibrin digest and purification steps on gradient (5-15%) SDS-PAGE. Lane I shows the fibrin digestion mixture containing the DD-E complex which dissociates to DD dimer and E fragment in SDS, fragments D and E. Lane 2 shows selected fraction pools from column 1 containing the DD-E complex (which is DD dimer and E fragment in SDS-PAGE) and lane 3 shows fragments D, E-2, and E-3. Lane 4 shows the purified fragment E-2 from column 2. Lane 5 contains molecular weight markers.
Effect offibrin(ogen) and its derivatives on the detection of plasmin by the assay (Table I) . Certain fibrin(ogen) derivatives may compete with the synthetic substrate for plasmin or may change the reactivity of plasmin through a conformational change, therefore, the effect ofthe ligands on the plasmin assay was evaluated. A range of plasmin concentrations (0-100 nM) were tested. Only fragment E-2 induced a slight stimulation in the plasmin assay relative to the buffer control value, whereas Desafib and FCB-2 induced slight inhibition, which was greatest at lower concentrations of plasmin (Table I) .
Promotion ofplasmin generation byfibrin(ogen) and its derivatives (Figs. 2, A-D) . Plasmin generation by pro-UK was promoted only by fragment E-2 (curve 1). The other fragments induced slight inhibition (curves 3-5) compared with the buffer control (curve 2). This slight inhibition was probably due to the effect of these fragments on the plasmin assay (see above) (Fig. 2 A) .
Negligible plasminogen activation was seen with the Ala-158-pro-UK at twice the concentration of the other activators, reflecting the low intrinsic activity of this mutant and its resistance to plasmin activation (curve 3). However, in the presence of fragment E-2, significant plasmin generation occurred (curve 1), the promotion being qualitatively comparable to that obtained with pro-UK (Fig. 2 B) . The negative OD is related to the background noise.
The quantitative difference, reflected by the scales used on the y-axis of Fig. 2, A and B, is due to the fact that pro-UK but not Ala-158-pro-UK is activated during the time course, thereby amplifying plasmin generation.
By contrast, t-PA induced plasminogen activation was not promoted by fragment E-2 (curve 5), being identical to the buffer control (curve 4). Instead, substantial promotion of .f^ fib (curve 2). A moderate promotion ofplasmin generation was also induced by fibrinogen (curve 3) (Fig. 2 C) . Plasmin generation by UK (curve 3) was not significantly promoted by FCB-2 (curve 2) or any ofthe fibrin(ogen) preparations. The slight promotion by fragment E-2 (curve 1) and slight inhibition by Desafib (curve 4), fibrinogen (curve 5), and CPB-treated fibrinogen (curve 6) being similar to the effect induced by the ligands on the assay as shown in Table I ( Fig. 2 D) .
Effect ofplasmin and CPB treatment of FCB-2, Desafib, andfibrinogen on plasmin generation by t-PA (Fig. 3 A) . Pretreatment of FCB-2 with plasmin in order to expose a COOHterminal lysine, slightly but reproducibly, potentiated its promotion of plasmin generation by t-PA (curve I vs. 2). This effect was reversed by subsequent treatment of FCB-2 with CPB (curve 3). Similarly, CPB attenuated the promotion of plasmin generation by Desafib (curve 4 vs. 5). CPB treatment of fibrinogen had no effect on its promotion ofplasmin generation by t-PA (curve 6 vs. 7). In the absence of ligands, little plasmin generation occurred (curve 8) (Fig. 3 A) .
CPB treatment offragment E-2 and plasmin pretreatment ofFCB-2 on plasmin generation by pro-UK and Ala-158-pro-UK (Fig. 3 , B and C). CPB treatment offragment E-2 (curve 1), to remove the COOH-terminal lysines, eradicated its promotion of plasmin generation by pro-UK (curve 2) bringing it down to that ofthe buffer control (curve 3). Plasmin pretreated FCB-2 had no effect on pro-UK activity and plasmin generation remained below (curve 4) that of the buffer control, indicating that the Aa-chain COOH-terminal lysine which augmented t-PA activity (see Fig. 3 A) had no effect on pro-UK activity (Fig. 3 B) .
The results obtained with the Ala-158-pro-UK were similar. The CPB treatment of fragment E-2 (curve 1) eradicated its promotion ofplasmin generation (curve 2) which became comparable to the buffer control (curve 3). Plasmin pretreatment of FCB-2 did not induce any promotion of plasmin generation (curve 4). Only quantitative differences from pro-UK were seen due to the nonactivatability of the mutant (Fig. 3 C) .
Control experiments with CPB showed that it had no effect on plasmin generation by any of the activators.
Comparison of the reaction rates of the activators in the presence offibrin(ogen) and its derivatives (TableII). A comparison of the reaction rates (mean±SD) of t-PA, UK, pro-UK, and Ala-1 58-pro-UK in the presence or absence offibrin(ogen) and its derivatives, with or without CPB treatment, is shown in Table II . The rate was obtained from the absorbance (A A4101490n, X 106/min2) and curve fitting as described above.
The rate of t-PA-induced plasmin generation was significantly promoted by all fragment D-bearing ligands (FCB-2, Desafib, fibrinogen). There was significant potentiation seen in association with plasmin-pretreatment of FCB-2, an effect which was nullified by CPB. The maximum rate obtained for * Because UK generation influences the reaction rate induced by pro-UK, it has been designated pro-UK/UK (n = 4).
t-PA was 1,001.3±8.4 (with plasmin-pretreated FCB-2) compared with a buffer control rate for t-PA of 13.0±2.2, corresponding to a 77-fold promotion by the ligand. By contrast, the reaction rates ofAla-158-pro-UK and pro-UK/UK were significantly promoted (compared with the buffer control value) exclusively by fragment E-2 (when not CPB-treated). However, the absolute rates obtained were far less, being 6.6±0.1 and 54.0±2.2 for Ala-158-pro-UK and pro-UK/UK respectively, corresponding to a two to threefold promotion. This large quantitative difference at low, equimolar (1 ,uM) concentrations of the ligands is believed to reflect the 20-200-fold lower Km of t-PA in the presence of a ligand (0.003-0.33 3gM) (11, 12) compared with that ofeither mutant pro-UK (13) or pro-UK (14) . This explanation was supported by the findings shown in Figure 4 . The UK reaction rate was 591.5±7.3 and was little effected by the ligands (Table II) .
Promotion ofAla-158-pro-UK-inducedplasminogen activation by fragment E-2 (Fig. 4) . The ratio of the reaction rates with and without fragment E-2 (V+E.2/V-E2) was plotted against the fragment E-2 concentration. An approximately linear promotion was obtained which was 148.9-fold at the highest concentration of fragment E-2 (20 AM). The latter figure corresponds to a reaction rate which approaches that of UK, because the latter has an activity 200-fold greater than that of pro-UK or Ala-158-pro-UK (3, 5) . The promotion by fragment E-2 was not brought to plateau and remained linear at the highest concentration of fragment E-2 tested (Fig. 4) .
In the presence ofequivalently high concentrations ofFCB-2 (20 MM), less than fivefold potentiation of Ala-158-pro-UK plasminogen activating activity was observed (data not shown). 
Discussion
Plasminogen activation by t-PA is greatly promoted by fibrin to which it has a strong affinity (15 (16) . This promotion was attenuated by the inclusion of CPB in the reaction mixture, indicating that COOH-terminal lysines generated during the reaction had some augmenting effect. Similarly, pretreatment of FCB-2 by plasmin augmented its potentiation of plasmin generation by t-PA, an effect which was also reversed by CPB. This augmentation by plasmin pretreatment of FCB-2 has been previously reported by Beckman et al. (12) and is believed to be related to the binding of kringle-2 of t-PA by a COOH-terminal lysine as suggested by deVries et al. (18) . By contrast to fragment D, the COOH-terminal lysines on fragment E appear not to interact similarly with t-PA, because fragment E-2 had no promoting effect on plasminogen activation by t-PA.
In contrast to t-PA, plasminogen activation by pro-UK or Ala-158-pro-UK was not stimulated by FCB-2, Desafib or fibrinogen, indicating that pro-UK did not preferentially activate plasminogen bound to intact fibrin on the D fragment. Moreover, plasmin pretreatment of FCB-2 had no effect, indicating that a COOH-terminal lysine on partially degraded fragment D is not one of the COOH-terminal lysines involved in the promotion of plasminogen activation by pro-UK. Instead, plasminogen activation by pro-UK or by Ala-158-pro-UK was significantly promoted only by fragment E-2. The stimulation of Ala-158-pro-UK was particularly noteworthy because it had no measurable activity against plasminogen in the absence of fragment E-2. Stimulation by fragment E-2 was lost in the presence of CPB.
Therefore, it appears that the promotion of pro-UK-induced plasmin generation is specifically related to the COOHterminal lysine(s) on fragment E, represented in the present study by fragment E-2. Varadi and Patthy have previously shown that all three COOH-terminal lysines are needed for the maintenance of the plasminogen binding site on fragment E (8) , and they may be also needed for the induction ofa specific conformational change. A conformational alteration in plasminogen has previously been proposed as the principal mechanism by which the fibrin specificity of pro-UK is mediated (4).
At low, equimolar concentrations ofthe ligands (1 gM), the absolute rate ofplasmin generation by Ala-158-pro-UK or pro-UK in the presence of fragment E-2 was only a fraction ofthat induced by FCB-2 on t-PA (Table II) . This quantitative difference may reflect the Km of t-PA in the presence of this ligand (15) which is 20-200-fold lower than that of Lys-158 mutant pro-UK (13) or pro-UK (14) . This interpretation is supported by the major promotion ofAla-158-pro-UK-induced plasminogen activation which was observed when the concentration of fragment E-2 was increased. At a fragment E-2 concentration of 20 uiM, a 148.9-fold promotion was obtained, causing the reaction rate of Ala-158-pro-UK to approach that UK against Glu-plasminogen, which is 200-fold higher (3, 5) . Moreover, the promotion remained linear at the highest concentration of fragment E-2 tested (Fig. 4) .
The present findings that t-PA and pro-UK are promoted by different fibrin fragments is consistent with certain previous observations. These include the complementary and synergistic fibrinolytic effects obtained with combinations of t-PA and pro-UK (1) or t-PA and a Lys-158 plasmin-resistant mutant pro-UK (Val 158) (19), and the lag phase of pro-UK, but not t-PA-induced clot lysis. Because fragment E-bound plasminogen is available only in partially degraded fibrin, the attenuation of the lag phase of pro-UK by plasmin pretreatment of clots (1) is also consistent with the present findings.
In conclusion, it was shown that t-PA and pro-UK-induced plasmin generation is promoted by entirely different fibrin(ogen) fragments, suggesting that each activator is selective and restricted in its activity against fibrin-bound plasminogen. Neither activator activated the alternate fibrin-bound plasminogen any better than it did unbound plasminogen. Therefore, neither t-PA nor pro-UK may be capable of efficiently activating more than a portion of the available fibrin-bound plasminogen in a clot. This may explain their high dose requirements when used alone in therapeutic thrombolysis. The complementary nature of fibrin-dependent plasminogen activation by t-PA and pro-UK provides a rationale for using them together, especially in a sequential combination.
